Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
- PMID: 37459140
- DOI: 10.1001/jama.2023.11702
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
Comment in
-
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.JAMA. 2023 Aug 8;330(6):507-509. doi: 10.1001/jama.2023.11703. JAMA. 2023. PMID: 37459124 No abstract available.
-
Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704. JAMA. 2023. PMID: 37459138 No abstract available.
Comment on
-
Ushering in a New Era of Alzheimer Disease Therapy.JAMA. 2023 Aug 8;330(6):503-504. doi: 10.1001/jama.2023.11701. JAMA. 2023. PMID: 37459123 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
